Latest News From Lumira Ventures

Zymeworks Closes Previously Announced Public Offering

Ahmed Khan Portfolio News, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today that it has closed its previously announced underwritten public offering (the “Offering”) of 6,210,000 common shares, including …

Zymeworks and Celgene Expand Bispecific Antibody Collaboration

Ahmed Khan Portfolio News, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ …

Zymeworks Announces the Successful Achievement of a Research Milestone with Lilly in Bispecific Antibody Collaboration

admin Portfolio News, Zymeworks

January 05, 2017 05:00 AM Eastern Standard Time VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced the successful …

Zymeworks Doses First Patient in Phase 1 Trial of ZW25, a Novel Bi-Specific Antibody for the Treatment of HER2-Expressing Cancers

admin Portfolio News, Zymeworks

Vancouver, Canada – Zymeworks Inc., a biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics, including bi-specific antibodies and drug conjugates for the treatment of cancer, announced today that the first patient was dosed in a Phase 1 clinical trial …

Zymeworks Announces the Successful Achievement of a Milestone with Lilly in Bi-Specific Antibody Therapeutics Collaboration

admin Portfolio News, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. today announced the successful achievement of a research milestone in its collaboration with Eli Lilly and Company in the development of a novel immune-modulating bi-specific antibody using Zymeworks’ proprietary Azymetric™ platform. In accordance with the …

Zymeworks and Kairos Therapeutics Enter into Strategic Partnership and Optional Merger Agreement to Develop Antibody Drug Conjugates and Bi-Specific Antibodies

admin Portfolio News, Zymeworks

Vancouver, Canada – January 8, 2016: Zymeworks Inc. and Kairos Therapeutics Inc., both privately-held biotech companies headquartered in Vancouver, today announced they have entered into a strategic partnership whereby Zymeworks, a leader in the development of bi-specific and multi-specific antibodies, …